top of page

NEWS
Filter posts by:
We Work For Health Statement on Administration’s Executive Order
We Work For Health released the following statement on the Trump Administration’s April 15 executive order regarding the Inflation...
15 hours ago
New Research Reveals the Devastating Impact of the Inflation Reduction Act’s “Pill Penalty” on Small Molecule Medicines
Small-molecule drug investment has fallen 68%—and 74% for diseases mainly affecting Medicare patients—since the IRA was introduced FOR...
3 days ago
Capitol Hill Briefing Unveils New Data Behind the ‘Epic’ EPIC Act
The lead sponsors of the Ensuring Pathways to Innovative Cures (EPIC) Act addressed a room full of Congressional office employees and...
5 days ago
Join Us: We Work For Health Hosts Special Event About the Ongoing Threats of the IRA
Learn about the Inflation Reduction Act—and how it’s threatening America’s biopharmaceutical ecosystem and our nation’s Medicare-aged...
Apr 3
Protecting Innovation and Patient Access: Why Congress Must Reject Anti-Patent Legislation
Innovation often comes in increments. The first smartphones could not record video or take front-facing photos, and there certainly was...
Apr 2
Biopharma-Funded Clinical Trials Drive Billions in Economic Impact, Advance Medical Research & Treatments
A new report highlights the significant investments and economic impact generated by clinical trials funded by the biopharmaceutical...
Mar 14
We Work For Health Applauds Senate Introduction of the EPIC Act
Legislation would address the “pill penalty” and strengthen U.S. leadership in pharmaceutical innovation. WASHINGTON, D.C. (March 6,...
Mar 6
We Work For Health and Stakeholders Discuss Impact of the IRA
Healthcare costs continue to be a significant concern for Americans. While policies like government price controls under the Inflation...
Feb 28
New Report Illustrates Why Congress Must Fix the “Pill Penalty”
Small-molecule drugs, which typically come in pill or tablet form, have long been the backbone of modern medicine, treating everything...
Feb 27
We Work For Health Applauds Lawmakers for Re-introducing the Ensuring Pathways to Innovative Cures (EPIC) Act
Bipartisan legislation would correct the IRA’s “pill penalty,” which will have a chilling effect on the prescription drug ecosystem...
Feb 25
WWFH's Executive Director Asks White House to Pause IRA and Prioritize Patient Costs and Innovation
We Work For Health Executive Director Dan Leonard's recently wrote a letter to the White House, encouraging a pause in the implementation...
Jan 27
Second Round of Medicare Drug Price Controls Perpetuates Flawed, Harmful Policy
FOR IMMEDIATE RELEASE JAN. 17, 2025 WASHINGTON, DC (Jan. 17, 2025) – The Centers for Medicare and Medicaid Services’ (CMS) announcement...
Jan 17
PREVIEW: The Impact of the Small Molecule “Pill Penalty” Two Years Into the IRA
Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment,...
Jan 14
Achieving Health Equity: A Commitment to Community and Policy Engagement
At We Work For Health (WWFH), our commitment to fostering health equity across the nation goes beyond advocacy—it extends to tangible,...
Jan 2
Workforce Development: The Engine of Innovation in the Biopharmaceutical Industry
The biopharmaceutical industry is the backbone of America's innovative economy, supporting more than 4.9 million jobs across the United...
Jan 2
We Work For Health Statement in Support of Biosimilars Legislative Solution
We Work For Health Executive Director Dan Leonard released the following statement in support of recently introduced legislation that...
Dec 10, 2024
Senate Judiciary Committee Considered Key Bills to Support IP Rights and Encourage Patent Investment
As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing to consider a number of critical bills...
Nov 12, 2024
New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from IRA
Washington, DC – New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation...
Oct 9, 2024
New Report Provides Critical Context to Government Claims of IRA So-Called Drug Savings and Explores the Law’s True Impact on Patient Costs
New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...
Oct 9, 2024
Recognizing the Hatch-Waxman Act’s 40th Anniversary on Capitol Hill
The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the...
Oct 1, 2024
We Work For Health Urges Senate HELP Committee to Reject Bills that Undermine IP and Patent Protections
Dear Chairman Sanders, Ranking Member Cassidy, and Members of the Committee: The American medical innovation infrastructure that has...
Sep 20, 2024
Fact Checking the Inflation Reduction Act’s Real-World Impact and Consequences
As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...
Sep 17, 2024
Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem
In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act – established a...
Sep 9, 2024
Watch: California leaders highlight biopharma innovation, collaboration and policy progress
During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor,...
Sep 5, 2024
Don’t Throw Out 40 Years of Innovation by Dismantling IP Protections
While the 1980s is best remembered for its questionable fashion and cultural influence, two critical policies from early in the decade...
Aug 29, 2024
Policymakers: Protect & Maximize U.S. Intellectual Property for Biopharma Innovation that Helps Patients
American innovation depends on a strong, robust intellectual property system that allows health care advances to save and enhance lives....
Aug 28, 2024
State-By-State Data Showcases Biopharma’s Impact on Local Economics and Innovation
We Work For Health recently unveiled a new set of one-page resources designed to highlight the significant impact of the...
Aug 27, 2024
Protecting the Drug Discovery Pipeline
A version of this blog originally published as an op-ed in The Center Square in Arizona. We're sharing it here with additional updates...
Aug 22, 2024
We Work For Health Statement on IRA Medicare Price Setting Announcement
Aug. 15, 2024 FOR IMMEDIATE RELEASE WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...
Aug 15, 2024
A Guide to Understanding the Administration’s Announcement on Medicare Drug Pricing
The Biden administration this week is expected to claim victory on its stated goal of lowering drug prices for seniors. While the...
Aug 14, 2024
10 Reasons Biopharma Innovation Needs Strong IP Protections
By Dan Leonard, WWFH Executive Director Intellectual property (IP) plays a crucial role in the success of the pharmaceutical and biotech...
Aug 6, 2024
Inflation Reduction Act Causes Medicare Part D Premiums To Increase Again
On Monday, the Centers for Medicare and Medicaid Services (CMS) announced 2025 premiums for Medicare Part D plans will increase again....
Jul 30, 2024
We Work For Health's Comments on IPAY 2027 draft guidance
Meena Seshamani, M.D., Ph.D. CMS Deputy Administrator and Director of the Center for Medicare Centers for Medicare & Medicaid Services...
Jul 2, 2024
New Research Shows Alarming Drop in Neurology Innovation Due To IRA’s Small Molecule ‘Pill Penalty’
During an event on Capitol Hill this week, California Rep. Scott Peters highlighted a graphic that clearly illustrates the distorted...
Jun 28, 2024
New Report Demonstrates How the IRA’s “Pill Penalty” is Setting Back the Development of Non-Opioid Pain Medicine
Despite the significant demand for effective non-opioid medications for the treatment of pain, a recent report from the Pioneer Institute...
Jun 25, 2024
We Work For Health Honors Rep. Scott Peters with Healthcare Leadership Innovation Award
SAN DIEGO – At a We Work For Health roundtable on June 20, the organization and its partners honored Rep. Scott Peters (CA-50) with the...
Jun 24, 2024
As NIST Finalizes March-in Guidance, Innovation Community Continues to Convey Opposition
The National Institute of Standards and Technology (NIST) may soon finalize its controversial proposal to expand the scope of the...
Jun 21, 2024
New Data Reveals Strong Economic Impact of Texas Biopharmaceutical Industry
For Immediate Release June 5, 2024 Contact: Lisa Glass 512-695-3569 / lglass@rosscomm.com New Data Reveals Strong Economic Impact of...
Jun 10, 2024
The Inflation Reduction Act is Hurting Medicare Access and Increasing Patients’ Costs
This week, the largest not-for-profit health insurance provider in Missouri, Blue KC, announced it will leave the Medicare Advantage...
Jun 5, 2024
CMS Finalizes Policy to Facilitate Faster Biosimilar Uptake but Follow-on Policies and Actions Still Needed
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule allowing Medicare Advantage and Part D health plans to...
May 1, 2024
Statement by We Work For Health Executive Director Dan Leonard on World IP Day
FOR IMMEDIATE RELEASE April 26, 2024 WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...
Apr 26, 2024
Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline
Today, President Biden highlighted the administration’s current and future efforts to lower healthcare costs. The good news is recent...
Apr 3, 2024
Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma
We Work For Health recently convened a conversation to explore the impact policy decisions have on the biopharmaceutical industry and...
Mar 28, 2024
Vendors Power America's Biopharmaceutical Industry
We Work For Health recently released new employment, vendor and supplier expenditure data that showcases the vital contributions of these...
Mar 12, 2024
President Biden’s State of the Union Call for IRA Expansion Hurts Patients, Workers, and U.S. Leadership
During his State of the Union address Thursday night, President Biden called for Congress to expand the Inflation Reduction Act to...
Mar 7, 2024
House Reviews the ORPHAN Cures Act
On Feb. 29, the House Energy and Commerce Subcommittee on Health held a hearing to review a number of bills that impact those living with...
Feb 29, 2024
Biden's Attempts to Lower Drug Costs Are Sabotaging Biosimilar Competition and Are Destined For Failure
The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...
Feb 13, 2024
Statement By We Work For Health on the Ensuring Pathways to Innovative Cures (EPIC) Act
Feb. 01, 2024 FOR IMMEDIATE RELEASE Washington, DC (Feb. 01, 2024) – We Work For Health has issued the following statement from Executive...
Feb 1, 2024
The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments
The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade...
Jan 31, 2024
How American Patients Will Bear the Cost of Government Price Controls
Today, patients in the United States have greater access to the latest lifesaving and life-altering medical treatments than anywhere...
Jan 31, 2024
bottom of page